This article is more than 5 years old. Information may no longer be current.
Intravitreal, topical medications yield similar post-cataract outcomes
Cataract surgery with either topical or intravitreal antibiotics, steroids and NSAIDs yielded similar outcomes, although patients preferred the injection, according to a study.
The prospective, randomized study included 25 patients who underwent bilateral cataract surgery, using the contralateral eye as a comparator.
At the first surgery, patients either received a transzonular intravitreal injection of Tri-Moxi-Vanc (triamcinolone, moxifloxacin and vancomycin intraocular solution, Imprimis) or a regimen of topical prednisolone, moxifloxacin and ketorolac formulation, followed by a prednisolone and ketorolac formulation (both Imprimis) postoperatively. When second eye surgery was done, the opposite treatment protocol was performed. For patients receiving the injection in their first surgery, second surgery was typically carried out 2 weeks postoperatively.
Average patient age was 69 years.
Primary outcome measures were changes in IOP from baseline and changes in corneal and macular thickness. Patients evaluated pain, quality of vision and satisfaction, and were asked to declare a preference of regimen.
Study results showed an insignificant between-group difference in IOP. In addition, IOP increased insignificantly over time.
The between-group difference in central macular thickness was insignificant at 1 week and 1 month.
Central corneal thickness was significantly greater than baseline at 1 day. However, the between-group difference was insignificant.
Pain scores were similar in both groups.
Patient satisfaction was similar in both groups but significantly more patients preferred the injection (P < .01).
Five study-related minor adverse events were reported. All cases were treated and were resolved. Two events in the topical group and three were in the injection group.
Disclosure: The study authors report no relevant financial disclosures.